Created On: 2020-07-15
Record Count: 3
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 28853
â€œLicenceâ€ shall mean an exclusive, worldwide, sublicenseable licence to use the Licensed Information and under the Patents, for the research, development, production, marketing and sale of Products, subject to the provisions of clause 4 below and the other terms and conditions of this Agreement.
U.S.A* 08/913,994 – 6,613,536
A method to dissolve the peptide (hCDR1) in PBS for the tolerogenic administration.
Mode of injection of hCDR1 for the prevention of an autoimmune response.
Characterization of the isotypes of the antibodies produced following a chronic treatment with hCDR1.
Binding of hCDR1 to MHC class II on APC in comparison with control peptides.
Determination of complement C3 levels in sera of mouse models and effects of treatment with hCDR1.
Assays for the evaluation of the effects of treatment with hCDR1 in the presence of immunosuppressive drugs (such as Methotrexate, Mofetil Mycophenolate, Immuran) used for the treatment of lupus (especially lupus nephritis).
Methods to assess the effects of treatment with hCDR1 on CNS lupus (pathology and behavior dysfunction) in spontaneous and induced experimental SLE.
Determination of anti-NMDA specific antibodies in sera of mice with induced lupus and the effects of hCDR1 on the latter.
Induction of neurogenesis and expression of BDNF in brains of SLE afflicted mice following treatment with hCDR1.
Methods to determine B cell dysfunction and the effect of hCDR1 on the latter especially in the target organs of lupus, namely, brain and kidney.
Evaluation of hCDR1 activity using a short term in vitro assay. This method was used in one of our publications and is written in the Methods section. However, because this technology can be used in the future to determine whether a patient might be a responder to the treatment of hCDR1 (which is not mentioned in the publication) we think that it might be the most important know how of the whole list.
IPSCIO Record ID: 281494
IPSCIO Record ID: 28107